ENTPD1 and neoplasm: In case of P2X7 WT mice with implanted tumours, the use of antagonists, such as A740003, causes a downregulation of CD39 and CD73 in Teff and dendritic cells, suggesting that blocking the receptor may lead to a reduction in the degradation of ATP in adenosine [4], which triggers, in turn, an anti-inflammatory effect.